R&D Costs of New Medicines: A Landscape Analysis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Over the years, questions have been raised over R&D costs of new medicines. The aim of this study is to conduct a landscape review of the (drivers of) R&D costs of a new medicine derived from the peer-reviewed and grey literature. Included studies have drawn data either from confidential company surveys or from publicly available company financial statements, in addition to accessing the literature and medicine information databases. Although there were differences in methodology, parameter values, samples and time periods between studies, estimates of R&D costs per new medicine (accounting for the cost of failures) ranged from US$944m to US$2,826m (adjusted to 2019 prices). The evidence also suggested that R&D costs per new medicine have increased over time. A few studies have broken down total costs and showed that clinical development accounts for 50-58% of R&D costs per new medicine. R&D costs were influenced by costs of discovery and pre-clinical development, costs of clinical development, cost of capital, company and product profile. Finally, cost estimates are likely to be dynamic as the biopharmaceutical industry and the broader environment continue to evolve.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 2×
“Although a few studies break down R&D costs of new medicines into costs associated with different drivers (2, 11), there is a need to systematically provide estimates of individual cost components in future studies with a view to examine the relative importance of cost components and how their importance evolves over…”
BackgroundInnovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Wouters, O. J., McKee, M., & Luyten, J. (2020) · JAMA · doi:10.1001/jama.2020.1166 · Cited by 1,531
How much does it cost to research and develop a new drug? A systematic review and assessment
Schlander, M., Hernandez-Villafuerte, K., Cheng, C.-Y., Mestre-Ferrandiz, J., & Baumann, M. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01065-y · Cited by 360 · cited 1×
“Recently, a systematic review mainly analysed the relevant peer-reviewed literature, but did not consider consultancy reports on the topic (4).”
BackgroundPharmaceutical research and development: what do we get for all that money?
Light, D. W., & Lexchin, J. R. (2012) · BMJ · doi:10.1136/bmj.e4348 · Cited by 258 · cited 1×
“For instance, the literature generates pre-tax estimates and, hence, does not consider deductibility of R&D expenditure for taxation purposes (17).”
Background
Cited by
A systematic study of key elements underlying molecular property prediction
Deng, J., Yang, Z., Wang, H., Ojima, I., Samaras, D., & Wang, F. (2023) · Nature Communications · doi:10.1038/s41467-023-41948-6 · Cited by 213
“As revealed by a recent study 1 , the average cost of developing a new drug was ~1 billion dollars and has been ever increasing 2 .”
Laxminarayan, R., Impalli, I., Rangarajan, R., Cohn, J., Ramjeet, K., Trainor, B. W., Strathdee, S., Sumpradit, N., Berman, D., Wertheim, H., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00878-x · Cited by 111
Roadblocks confronting widespread dissemination and deployment of Organs on Chips
Alver, C. G., Drabbe, E., Ishahak, M., & Agarwal, A. (2024) · Nature Communications · doi:10.1038/s41467-024-48864-3 · Cited by 74
“The estimated average cost for pharmaceutical companies to bring a new drug to market is approximately2 billion dollars, and the process cantake upwards of 15 years 33,51 .”
NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned
Rasmussen, D. G. K., Anstee, Q. M., Torstenson, R., Golding, B., Patterson, S. D., Brass, C., Thakker, P., Harrison, S., Billin, A. N., Schuppan, D., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.11.028 · Cited by 41
Metadata
- Authors
- Simoens, S., & Huys, I.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2021-10-26
- Volume
- 8
- Pages
- 760762-760762
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W3209017840
- Cited by
- 87
- References
- 6
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: R&D Costs of New Medicines: A Landscape Analysis. https://app.cochat.ai/papers/10.3389/fmed.2021.760762
- The paper
- Simoens, S., & Huys, I. (2021). R&D Costs of New Medicines: A Landscape Analysis. Frontiers in Medicine. https://doi.org/10.3389/fmed.2021.760762
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.